REGN

1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street

01/02 11:00 am

Eosinophilic Esophagitis Market Insight, Epidemiology and Market Forecast to 2034

01/02 05:58 am

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

12/09 06:45 pm

Cancer Monoclonal Antibodies Market to Grow at a 18.4% CAGR through 2031 | SkyQuest Technology

12/09 08:10 am

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

12/04 02:00 pm

Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034

11/26 12:00 pm

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

11/16 11:16 am

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease

11/15 09:44 am

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

11/13 12:06 pm

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

11/13 08:00 am

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

11/06 05:11 am

Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight

11/04 02:00 pm

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

10/31 01:46 pm

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

10/28 04:20 am

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

10/24 08:00 am

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

10/18 05:05 pm

This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street

10/17 06:30 am

mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way

10/14 11:48 am

Should You Buy the Dip on This Top Growth Stock?

10/05 06:30 am

Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

10/01 01:00 pm

Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?

09/29 01:25 pm

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

09/27 11:17 am

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

09/27 07:00 am

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

09/25 08:04 am

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

09/24 09:15 am

Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease

09/11 09:35 am

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

09/11 07:00 am

Prediction: These 2 Companies Will Split Their Stocks by 2027

09/11 06:45 am

Communiqué de presse : Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée

09/11 01:05 am

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

09/11 01:05 am

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

09/11 01:04 am

Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

09/09 05:00 pm

GSK's Respiratory Drug Nucala Meets Goal in COPD Study

09/09 02:52 pm

Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030

09/05 09:10 am

Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033

08/23 11:47 am

Regeneron Provides Update on Biologics License Application for Linvoseltamab

08/20 06:45 pm

Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent

08/05 01:27 pm

The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Regeneron and Optex Systems

07/30 05:40 am

Top Analyst Reports for Goldman Sachs, RTX & Regeneron

07/29 02:00 pm

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients - Benzinga

07/23 10:38 am

Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling - Benzinga

07/15 08:19 am

Regeneron EVP LaRosa sells shares worth over $2 million - Investing.com

07/12 04:25 pm

Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD - GlobeNewswire

07/03 01:00 am

Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

06/28 07:00 am

Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

06/27 04:05 pm

Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down

06/27 10:38 am

Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

06/26 05:30 pm

Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?

06/18 01:22 pm

Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

06/16 06:10 am

Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry

06/14 11:49 am